

Kurt G Naber

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7805416/publications.pdf>

Version: 2024-02-01

137
papers

7,408
citations

61857

43
h-index

58464

82
g-index

163
all docs

163
docs citations

163
times ranked

6041
citing authors

#	ARTICLE	IF	CITATIONS
1	International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clinical Infectious Diseases</i> , 2011, 52, e103-e120.	2.9	2,194
2	The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 407-413.	1.1	315
3	Infective Complications After Prostate Biopsy: Outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, A Prospective Multinational Multicentre Prostate Biopsy Study. <i>European Urology</i> , 2013, 63, 521-527.	0.9	280
4	Surveillance Study in Europe and Brazil on Clinical Aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): Implications for Empiric Therapy. <i>European Urology</i> , 2008, 54, 1164-1178.	0.9	259
5	Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system. <i>International Journal of Antimicrobial Agents</i> , 2011, 38, 64-70.	1.1	158
6	Prevalence, Incidence Estimation, Risk Factors and Characterization of Chronic Prostatitis/Chronic Pelvic Pain Syndrome in Urological Hospital Outpatients in Italy: Results of a Multicenter Case-Control Observational Study. <i>Journal of Urology</i> , 2007, 178, 2411-2415.	0.2	149
7	Urinary tract infection in adults: research priorities and strategies. <i>International Journal of Antimicrobial Agents</i> , 2001, 17, 343-348.	1.1	139
8	EAU Guidelines for the Management of Genitourinary Tuberculosis. <i>European Urology</i> , 2005, 48, 353-362.	0.9	125
9	Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. <i>International Journal of Antimicrobial Agents</i> , 2009, 33, 111-119.	1.1	124
10	Hospital acquired urinary tract infections in urology departments: pathogens, susceptibility and use of antibiotics. <i>International Journal of Antimicrobial Agents</i> , 2006, 28, 91-107.	1.1	98
11	Social and economic burden of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT). <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 107-117.	0.7	96
12	Prostate Biopsy-related Infection: A Systematic Review of Risk Factors, Prevention Strategies, and Management Approaches. <i>Urology</i> , 2017, 104, 11-21.	0.5	92
13	Executive Summary: International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clinical Infectious Diseases</i> , 2011, 52, 561-564.	2.9	89
14	Chronic prostatitis--an infectious disease?. <i>Journal of Antimicrobial Chemotherapy</i> , 2000, 46, 157-161.	1.3	83
15	Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial. <i>Urologia Internationalis</i> , 2018, 101, 327-336.	0.6	81
16	The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients. Part II: Therapy and Prevention. <i>Urologia Internationalis</i> , 2018, 100, 271-278.	0.6	80
17	Review of the literature and individual patients' data meta-analysis on efficacy and tolerance of nitroloxoline in the treatment of uncomplicated urinary tract infections. <i>BMC Infectious Diseases</i> , 2014, 14, 628.	1.3	79
18	Uncomplicated Urinary Tract Infections. <i>Deutsches Arzteblatt International</i> , 2011, 108, 415-23.	0.6	77

#	ARTICLE	IF	CITATIONS
19	Healthcare-associated urinary tract infections in hospitalized urological patients—a global perspective: results from the GPIU studies 2003–2010. <i>World Journal of Urology</i> , 2014, 32, 1587-1594.	1.2	77
20	Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections. <i>International Journal of Antimicrobial Agents</i> , 2004, 23, 54-66.	1.1	75
21	Intravenous Doripenem at 500 Milligrams versus Levofloxacin at 250 Milligrams, with an Option To Switch to Oral Therapy, for Treatment of Complicated Lower Urinary Tract Infection and Pyelonephritis. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3782-3792.	1.4	74
22	Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study. <i>World Journal of Urology</i> , 2014, 32, 791-801.	1.2	71
23	Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003–2013. <i>World Journal of Urology</i> , 2016, 34, 1193-1200.	1.2	70
24	Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500mg) versus ciprofloxacin (500mg) in healthy volunteers receiving a single oral dose. <i>International Journal of Antimicrobial Agents</i> , 2006, 28, 551-559.	1.1	68
25	Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-comparative multicentre clinical trial with long-term follow-up. <i>International Journal of Antimicrobial Agents</i> , 2000, 14, 143-149.	1.1	63
26	Epidemiology, treatment and prevention of healthcare-associated urinary tract infections. <i>World Journal of Urology</i> , 2012, 30, 59-67.	1.2	62
27	The Global Prevalence of Infections in Urology Study: A Long-Term, Worldwide Surveillance Study on Urological Infections. <i>Pathogens</i> , 2016, 5, 10.	1.2	62
28	Multidisciplinary approach to prostatitis. <i>Archivio Italiano Di Urologia Andrologia</i> , 2018, 90, 227-248.	0.4	62
29	Prevention and treatment of uncomplicated lower urinary tract infections in the era of increasing antimicrobial resistance—non-antibiotic approaches: a systemic review. <i>Archives of Gynecology and Obstetrics</i> , 2019, 300, 821-828.	0.8	62
30	An update on uncomplicated urinary tract infections in women. <i>Current Opinion in Urology</i> , 2009, 19, 368-374.	0.9	61
31	Lomefloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis. <i>International Journal of Antimicrobial Agents</i> , 2002, 20, 18-27.	1.1	60
32	The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients: Part 1. <i>Urologia Internationalis</i> , 2018, 100, 263-270.	0.6	58
33	Efficacy and safety of the phytotherapeutic drug Canephron® N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia. <i>Research and Reports in Urology</i> , 2013, 5, 39.	0.6	56
34	Improved Classification of Urinary Tract Infection: Future Considerations. <i>European Urology Supplements</i> , 2016, 15, 71-80.	0.1	53
35	Survey on antibiotic usage in the treatment of urinary tract infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2000, 46, 49-52.	1.3	50
36	New Self-Reporting Questionnaire to Assess Urinary Tract Infections and Differential Diagnosis: Acute Cystitis Symptom Score. <i>Urologia Internationalis</i> , 2014, 92, 230-236.	0.6	49

#	ARTICLE	IF	CITATIONS
37	Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400mg to healthy volunteers. <i>International Journal of Antimicrobial Agents</i> , 2008, 31, 21-26.	1.1	48
38	Penetration of Ciprofloxacin into Prostatic Fluid, Ejaculate and Seminal Fluid in Volunteers after an Oral Dose of 750 MG. <i>Journal of Urology</i> , 1993, 150, 1718-1721.	0.2	47
39	Urinary Concentrations and Antibacterial Activities of Nitroxoline at 250 Milligrams versus Trimethoprim at 200 Milligrams against Uropathogens in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 713-721.	1.4	47
40	Oral levofloxacin 500mg once daily in the treatment of chronic bacterial prostatitis. <i>International Journal of Antimicrobial Agents</i> , 2008, 32, 145-153.	1.1	46
41	Human Urine Is Not Sterile - Shift of Paradigm. <i>Urologia Internationalis</i> , 2015, 94, 445-452.	0.6	46
42	Treatment of Urinary Tract Infections and Antibiotic Stewardship. <i>European Urology Supplements</i> , 2016, 15, 81-87.	0.1	45
43	Prostatitis and Male Pelvic Pain Syndrome. <i>Deutsches A&#x0308;rztblatt International</i> , 2009, 106, 175-83.	0.6	44
44	Management of bacterial prostatitis: whatâ€™s new?. <i>BJU International</i> , 2008, 101, 7-10.	1.3	43
45	Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections. <i>International Journal of Antimicrobial Agents</i> , 2002, 19, 95-103.	1.1	41
46	EAU Guidelines for the Management of Urogenital Schistosomiasis. <i>European Urology</i> , 2006, 49, 998-1003.	0.9	41
47	Cefuroxime axetil versus ofloxacin for short-term therapy of acute uncomplicated lower urinary tract infections in women. <i>Infection</i> , 1993, 21, 34-39.	2.3	39
48	Comparison of fosfomycin against fluoroquinolones for transrectal prostate biopsy prophylaxis: an individual patient-data meta-analysis. <i>World Journal of Urology</i> , 2018, 36, 323-330.	1.2	38
49	Therapy for prostatitis, with emphasis on bacterial prostatitis. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1667-1674.	0.9	34
50	Antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy: fosfomycin trometamol, an attractive alternative. <i>World Journal of Urology</i> , 2017, 35, 221-228.	1.2	32
51	Penetration of ofloxacin into prostatic fluid, ejaculate and seminal fluid. <i>Infection</i> , 1993, 21, 98-100.	2.3	31
52	French results of the ARESC Study: Clinical aspects and epidemiology of antimicrobial resistance in female patients with cystitis. Implications for empiric therapy. <i>MÃ©decine Et Maladies Infectieuses</i> , 2012, 42, 66-75.	5.1	31
53	Concentrations of cefpodoxime in plasma, ejaculate and in prostatic fluid and adenoma tissue. <i>Infection</i> , 1991, 19, 30-35.	2.3	29
54	Gatifloxacin 400mg as a single shot or 200mg once daily for 3 days is as effective as ciprofloxacin 250mg twice daily for the treatment of patients with uncomplicated urinary tract infections. <i>International Journal of Antimicrobial Agents</i> , 2004, 23, 596-605.	1.1	29

#	ARTICLE	IF	CITATIONS
55	Aspects of urinary tract infections and antimicrobial resistance in hospitalized urology patients in Asia: 10-Year results of the Global Prevalence Study of Infections in Urology (GPIU). <i>Journal of Infection and Chemotherapy</i> , 2018, 24, 278-283.	0.8	29
56	Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. <i>International Journal of Antimicrobial Agents</i> , 2004, 23, 41-53.	1.1	27
57	The Acute Cystitis Symptom Score for Patient-Reported Outcome Assessment. <i>Urologia Internationalis</i> , 2016, 97, 402-409.	0.6	25
58	A Randomized, Double-Blind, Parallel-Group, Multicenter Clinical Study of <i>Escherichia coli</i>-Lyophilized Lysate for the Prophylaxis of Recurrent Uncomplicated Urinary Tract Infections. <i>Urologia Internationalis</i> , 2015, 95, 167-176.	0.6	23
59	Short-term therapy of acute uncomplicated cystitis. <i>Current Opinion in Urology</i> , 1999, 9, 57-64.	0.9	23
60	Antibiotic treatment of uncomplicated urinary tract infection in premenopausal women. <i>International Journal of Antimicrobial Agents</i> , 2011, 38, 21-35.	1.1	21
61	Population Pharmacokinetics and Penetration into Prostatic, Seminal, and Vaginal Fluid for Ciprofloxacin, Levofloxacin, and Their Combination. <i>Chemotherapy</i> , 2011, 57, 402-416.	0.8	21
62	Reliability of Symptom-Based Diagnosis of Uncomplicated Cystitis. <i>Urologia Internationalis</i> , 2019, 102, 83-95.	0.6	21
63	Prevention of recurrent urinary tract infections. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2013, 65, 9-20.	3.9	21
64	Appropriate empiric antibiotic choices in health care associated urinary tract infections in urology departments in Europe from 2006 to 2015: A Bayesian analytical approach applied in a surveillance study. <i>PLoS ONE</i> , 2019, 14, e0214710.	1.1	20
65	Evaluation of the draft guidelines proposed by EMA and FDA for the clinical diagnosis of acute uncomplicated cystitis in women. <i>World Journal of Urology</i> , 2020, 38, 63-72.	1.2	20
66	Optimal dosage and duration of pivmecillinam treatment for uncomplicated lower urinary tract infections: a systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2017, 58, 96-109.	1.5	19
67	Nitroxoline in geriatric patients with lower urinary tract infection fails to achieve microbiologic eradication: a noncomparative, prospective observational study. <i>Clinical Microbiology and Infection</i> , 2018, 24, 434-435.	2.8	19
68	An assessment of temafloxacin in the treatment of chronic bacterial prostatitis. <i>Journal of Antimicrobial Chemotherapy</i> , 1991, 28, 87-96.	1.3	18
69	Recurrent Urinary Tract Infections: Uro-Vaxom [®] , a New Alternative. <i>European Urology Supplements</i> , 2009, 8, 762-768.	0.1	18
70	Management of Uncomplicated Recurrent Urinary Tract Infections. <i>European Urology Supplements</i> , 2016, 15, 95-101.	0.1	18
71	Reevaluation of the Acute Cystitis Symptom Score, a Self-Reporting Questionnaire. Part I. Development, Diagnosis and Differential Diagnosis. <i>Antibiotics</i> , 2018, 7, 6.	1.5	18
72	Additional assessment of Acute Cystitis Symptom Score questionnaire for patient-reported outcome measure in female patients with acute uncomplicated cystitis: part II. <i>World Journal of Urology</i> , 2020, 38, 1977-1988.	1.2	18

#	ARTICLE	IF	CITATIONS
73	A global perspective on improving patient care in uncomplicated urinary tract infection: expert consensus and practical guidance. <i>Journal of Global Antimicrobial Resistance</i> , 2022, 28, 18-29.	0.9	18
74	Acute Cystitis Symptom Score (ACSS): Clinical Validation of the Italian Version. <i>Antibiotics</i> , 2020, 9, 104.	1.5	17
75	Urinary Bactericidal Activity of Extended-Release Ciprofloxacin (1,000 Milligrams) versus Levofloxacin (500 Milligrams) in Healthy Volunteers Receiving a Single Oral Dose. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3947-3949.	1.4	16
76	Treatment of Urinary Tract Infections with Canephron® in Germany: A Retrospective Database Analysis. <i>Antibiotics</i> , 2021, 10, 685.	1.5	16
77	Editorial Commentary: Asymptomatic Bacteriuria—Shift of Paradigm. <i>Clinical Infectious Diseases</i> , 2012, 55, 778-780.	2.9	15
78	Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a one-year prospective, double-blind, placebo-controlled study. <i>World Journal of Urology</i> , 2014, 32, 1595-1603.	1.2	15
79	An open label, non-controlled, multicentre, interventional trial to investigate the safety and efficacy of Canephron® N in the management of uncomplicated urinary tract infections (uUTIs). <i>Clinical Phytoscience</i> , 2015, 1, .	0.8	15
80	Reevaluation of the Acute Cystitis Symptom Score, a Self-Reporting Questionnaire. Part II. Patient-Reported Outcome Assessment. <i>Antibiotics</i> , 2018, 7, 43.	1.5	15
81	Effect of Different Media on the Bactericidal Activity of Colistin and on the Synergistic Combination With Azidothymidine Against mcr-1-Positive Colistin-Resistant <i>Escherichia coli</i> . <i>Frontiers in Microbiology</i> , 2020, 11, 54.	1.5	15
82	The negative aftermath of prostate biopsy: prophylaxis, complications and antimicrobial stewardship: results of the global prevalence study of infections in urology 2010–2019. <i>World Journal of Urology</i> , 2021, 39, 3423-3432.	1.2	15
83	The Global Prevalence of Infections in Urology (GPUU) Study: A Worldwide Surveillance Study in Urology Patients. <i>European Urology Focus</i> , 2016, 2, 345-347.	1.6	14
84	Emerging drugs for bacterial urinary tract infections. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 375-397.	1.0	13
85	The revival of old antibiotics for treatment of uncomplicated urinary tract infections in the era of antibiotic stewardship. <i>Current Opinion in Urology</i> , 2017, 27, 127-132.	0.9	13
86	Should We Always Use Antibiotics after Urodynamic Studies in High-Risk Patients?. <i>BioMed Research International</i> , 2018, 2018, 1-5.	0.9	13
87	Metagenomics in diagnosis and improved targeted treatment of UTI. <i>World Journal of Urology</i> , 2020, 38, 35-43.	1.2	13
88	Fosfomycin Trometamol (3,000 mg) in Perioperative Antibiotic Prophylaxis of Healthcare-Associated Infections after Endourological Interventions: A Narrative Review. <i>Urologia Internationalis</i> , 2014, 92, 125-130.	0.6	12
89	Letter to the Editor: Diagnostic Criteria in Urological Diseases do not Always Match with Findings by Extended Culture Techniques and Metagenomic Sequencing of 16S rDNA. <i>Open Microbiology Journal</i> , 2016, 10, 23-26.	0.2	12
90	Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria. <i>Drugs</i> , 2022, 82, 533-557.	4.9	12

#	ARTICLE	IF	CITATIONS
91	Biomarkers in urinary tract infections - which ones are suitable for diagnostics and follow-up?. <i>GMS Infectious Diseases</i> , 2020, 8, Doc24.	0.5	11
92	The role of the Acute Cystitis Symptom Score questionnaire for research and antimicrobial stewardship. Validation of the Hungarian version. <i>Central European Journal of Urology</i> , 2018, 71, 134-141.	0.2	11
93	Condition-specific surveillance in health care-associated urinary tract infections as a strategy to improve empirical antibiotic treatment: an epidemiological modelling study. <i>World Journal of Urology</i> , 2020, 38, 27-34.	1.2	10
94	Validation of the American English Acute Cystitis Symptom Score. <i>Antibiotics</i> , 2020, 9, 929.	1.5	10
95	Does <i>Escherichia coli</i> have pathogenic potential at a low level of bacteriuria in recurrent, uncomplicated urinary tract infection?. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 105983.	1.1	10
96	Anti-Biofilm Effect of Octenidine and Polyhexanide on Uropathogenic Biofilm-Producing Bacteria. <i>Urologia Internationalis</i> , 2021, 105, 278-284.	0.6	10
97	Psychosocial burden of recurrent uncomplicated urinary tract infections.. <i>GMS Infectious Diseases</i> , 2022, 10, Doc01.	0.5	10
98	How the microbiome is influenced by the therapy of urological diseases: standard versus alternative approaches. <i>Clinical Phytoscience</i> , 2017, 3, .	0.8	9
99	Effect of a Herbal Therapy on Clinical Symptoms of Acute Lower Uncomplicated Urinary Tract Infections in Women: Secondary Analysis from a Randomized Controlled Trial. <i>Antibiotics</i> , 2019, 8, 256.	1.5	9
100	Novel Antibiotics in the Treatment of Urinary Tract Infections. <i>European Urology Focus</i> , 2019, 5, 10-12.	1.6	9
101	Treatment of Asymptomatic Bacteriuria Might Be Harmful. <i>Clinical Infectious Diseases</i> , 2015, 61, civ698.	2.9	8
102	Pefloxacin single-dose in the treatment of acute uncomplicated lower urinary tract infections in women: a meta-analysis of seven clinical trials. <i>International Journal of Antimicrobial Agents</i> , 1994, 4, 197-202.	1.1	7
103	Acute Cystitis Symptom Score questionnaire for measuring patient-reported outcomes in women with acute uncomplicated cystitis: Clinical validation as part of a phase III trial comparing antibiotic and nonantibiotic therapy. <i>Investigative and Clinical Urology</i> , 2020, 61, 498.	1.0	7
104	Prevention of recurrent urinary tract infections: bridging the gap between clinical practice and guidelines in Latin America. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721882408.	0.9	6
105	Transurethral Resection of the Prostate: are We Following the Guidelines? - Outcomes from the Global Prevalence of Infections in Urology (GPIU) Study. <i>Journal of Chemotherapy</i> , 2019, 31, 15-22.	0.7	6
106	Changes in the management of urinary tract infections in women: impact of the new recommendations on antibiotic prescribing behavior in France, between 2014 and 2019. <i>BMC Health Services Research</i> , 2021, 21, 612.	0.9	6
107	Antibiotic therapy - rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue. <i>Andrologia</i> , 2003, 35, 331-335.	1.0	5
108	Do Different Susceptibility Breakpoints Affect the Selection of Antimicrobials for Treatment of Uncomplicated Cystitis?. <i>Journal of Chemotherapy</i> , 2010, 22, 345-355.	0.7	4

#	ARTICLE	IF	CITATIONS
109	A new way to prevent urinary tract infections?. Lancet Infectious Diseases, The, 2017, 17, 467-468.	4.6	4
110	Urinary tract infections in patients with renal insufficiency and dialysis - epidemiology, pathogenesis, clinical symptoms, diagnosis and treatment.. GMS Infectious Diseases, 2021, 9, Doc07.	0.5	4
111	Levofloxacin in the Treatment of Urinary Tract Infections and Prostatitis. Journal of Chemotherapy, 2004, 16, 18-21.	0.7	3
112	Urinary Tract Infections. Antibiotics, 2014, 3, 375-377.	1.5	3
113	Studying ceftazidime-avibactam in selected populations. Lancet Infectious Diseases, The, 2016, 16, 621-623.	4.6	3
114	A step further in a vaccine for Escherichia coli. Lancet Infectious Diseases, The, 2019, 19, 565-567.	4.6	3
115	The gene profile of <i>Enterobacteriaceae</i> virulence factors in relation to bacteriuria levels between the acute episodes of recurrent uncomplicated lower urinary tract infection. Expert Review of Anti-Infective Therapy, 2021, 19, 1061-1066.	2.0	3
116	Clinical Validation of the Greek Version of the Acute Cystitis Symptom Score (ACSS)â€™Part II. Antibiotics, 2021, 10, 1253.	1.5	3
117	Linguistic validation and cognitive assessment of the French version of the Acute Cystitis Symptom Score questionnaire. Progres En Urologie, 2022, 32, 73-76.	0.3	3
118	UTI â€™ quo vadis? New alternatives to treat uncomplicated urinary tract infections. Clinical Phytoscience, 2019, 5, .	0.8	2
119	Recent research in urological infections. Nature Reviews Urology, 2020, 17, 65-66.	1.9	2
120	Linguistic and clinical validation of the acute cystitis symptom score in German-speaking Swiss women with acute cystitis. International Urogynecology Journal, 2021, 32, 3275-3286.	0.7	2
121	Pulmonary and intranasal delivery of thymoquinone-loaded nanoparticles for Mucormycosis & Covid-19. Precision Nanomedicine, 2021, 4, .	0.4	2
122	Translation and validation of the Korean version of acute cystitis symptom score. Investigative and Clinical Urology, 2022, 63, 221.	1.0	2
123	Understanding clinical variables to improve empirical antibiotic therapy for UTI. Nature Reviews Urology, 2019, 16, 695-696.	1.9	1
124	Healthcare-associated urinary tract infections in urology. GMS Infectious Diseases, 2021, 9, Doc05.	0.5	1
125	Antibiotic therapy of chronic bacterial prostatitis is more effective considering antibiotic susceptibility of all pathogens isolated. Investigative and Clinical Urology, 2022, 63, .	1.0	1
126	Targeted, immediate antibiotics following a positive dipstick test may be the optimal management strategy. Evidence-Based Medicine, 2010, 15, 90-91.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Letter to the Editor. International Journal of General Medicine, 2011, 4, 755.	0.8	0
128	Working on a Dream. European Urology Supplements, 2016, 15, 69-70.	0.1	0
129	Editorial Comment. Journal of Urology, 2017, 198, 114-115.	0.2	0
130	Epidemiological study of the prevalence of cystitis in women of the Voronezh region. Experimental and Clinical Urology, 2021, 14, 10-18.	0.0	0
131	Principles of Bacterial Urinary Tract Infections and Antimicrobials. , 2011, , 91-103.		0
132	Prescribing Behavior in Urinary Tract Infection. Deutsches Arzteblatt International, 2012, 109, 876-7.	0.6	0
133	Review of the Phytoeering Research & Experience Summit (PRES) 2019 –building bridges between nature’s healing potential and evidence-based medicine - 20 years of phytoeering. Clinical Phytoscience, 2020, 6, .	0.8	0
134	UTI – Quo Vadis? New Alternatives to Treat Uncomplicated Urinary Tract Infections. Health of Man, 2020, .	0.1	0
135	Editorial Comment. Journal of Urology, 2020, 203, 577-578.	0.2	0
136	Calculated parenteral initial treatment of bacterial infections: Infections of the kidneys and the genito-urinary tract. GMS Infectious Diseases, 2020, 8, Doc12.	0.5	0
137	Bayberry in the treatment of acute uncomplicated cystitis (BRUMI): protocol of a multicentre, randomised double-blind clinical trial. BMJ Open, 2022, 12, e057982.	0.8	0